Cambridge Investment Research Advisors Inc. Sells 14,680 Shares of Intrexon Corporation (XON)
Cambridge Investment Research Advisors Inc. cut its position in shares of Intrexon Corporation (NYSE:XON) by 17.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 67,990 shares of the biotechnology company’s stock after selling 14,680 shares during the period. Cambridge Investment Research Advisors Inc. owned 0.06% of Intrexon Corporation worth $1,638,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the stock. Federated Investors Inc. PA bought a new stake in Intrexon Corporation during the second quarter worth about $172,000. Pacer Advisors Inc. boosted its stake in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after buying an additional 1,305 shares during the last quarter. SG Americas Securities LLC bought a new stake in Intrexon Corporation during the first quarter worth about $164,000. Cullinan Associates Inc. bought a new stake in Intrexon Corporation during the second quarter worth about $201,000. Finally, John G Ullman & Associates Inc. bought a new stake in Intrexon Corporation during the second quarter worth about $212,000. Institutional investors own 82.27% of the company’s stock.
Shares of Intrexon Corporation (XON) opened at 20.17 on Friday. The company’s market capitalization is $2.43 billion. The company’s 50 day moving average is $20.51 and its 200-day moving average is $21.63. Intrexon Corporation has a 52 week low of $17.03 and a 52 week high of $32.90.
Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business had revenue of $54.40 million for the quarter, compared to analyst estimates of $57.17 million. During the same quarter in the prior year, the firm posted ($0.42) earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts expect that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Cambridge Investment Research Advisors Inc. Sells 14,680 Shares of Intrexon Corporation (XON)” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/cambridge-investment-research-advisors-inc-sells-14680-shares-of-intrexon-corporation-xon/1537721.html.
A number of equities research analysts have issued reports on the company. Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub cut shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research cut shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Intrexon Corporation currently has an average rating of “Hold” and an average target price of $37.60.
In other news, COO Andrew J. Last purchased 2,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were acquired at an average price of $19.99 per share, with a total value of $39,980.00. Following the completion of the purchase, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Randal J. Kirk purchased 132,625 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were purchased at an average cost of $18.85 per share, for a total transaction of $2,499,981.25. The disclosure for this purchase can be found here. Insiders have bought 144,569 shares of company stock worth $2,719,429 in the last ninety days. 55.10% of the stock is currently owned by insiders.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.